Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 11/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL651235 | 1.00 | HPGD (0.42) | HPGDAURKBRNASELCHEK2DYRK3 | |
| SCHEMBL651234 | 0.84 | HPGD (0.48) | HPGDRNASELDYRK3 | |
| SCHEMBL711444 | 0.78 | CHEK2 (0.35) | HPGDAURKBCHEK2 | |
| SCHEMBL711442 | 0.78 | CHEK2 (0.35) | HPGDAURKBCHEK2 | |
| SCHEMBL10176546 | 0.74 | HPGD (0.48) | HPGD | |
| SCHEMBL651664 | 0.73 | MAPT (0.42) | HPGD | |
| SCHEMBL651663 | 0.73 | MAPT (0.42) | HPGD | |
| SCHEMBL649194 | 0.73 | MAPT (0.43) | HPGDDYRK3 | |
| SCHEMBL649193 | 0.73 | MAPT (0.43) | HPGDDYRK3 | |
| SCHEMBL652067 | 0.72 | MEN1 (0.46) | HPGDDYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423204-A1 | THIAZOLIDINONE DERIVATIVE | SBI Biotech Co., Ltd. (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-8119812-B2 | Thiazolidinone derivative | SBI BIOTECH CO., LTD. (JP) | 2012-02-21 | — | — | US | disclosed |
| US-20110190299-A1 | THIAZOLIDINONE DERIVATIVE | SBI BIOTECH CO., LTD. (JP) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190299-A1 | THIAZOLIDINONE DERIVATIVE | CDC7, CDK17, CDCA2 | HPGD 3970/4885AURKB 40/4885RNASEL 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.